SG11201401576WA - Etanercept formulations stabilized with amino acids - Google Patents

Etanercept formulations stabilized with amino acids

Info

Publication number
SG11201401576WA
SG11201401576WA SG11201401576WA SG11201401576WA SG11201401576WA SG 11201401576W A SG11201401576W A SG 11201401576WA SG 11201401576W A SG11201401576W A SG 11201401576WA SG 11201401576W A SG11201401576W A SG 11201401576WA SG 11201401576W A SG11201401576W A SG 11201401576WA
Authority
SG
Singapore
Prior art keywords
amino acids
etanercept formulations
formulations stabilized
stabilized
etanercept
Prior art date
Application number
SG11201401576WA
Other languages
English (en)
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201401576WA publication Critical patent/SG11201401576WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
SG11201401576WA 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids SG11201401576WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060738 WO2013059405A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids

Publications (1)

Publication Number Publication Date
SG11201401576WA true SG11201401576WA (en) 2014-10-30

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Family Applications After (5)

Application Number Title Priority Date Filing Date
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Country Status (27)

Country Link
US (21) US9302002B2 (ru)
EP (6) EP2768532A4 (ru)
JP (6) JP6113176B2 (ru)
KR (7) KR20140091706A (ru)
CN (6) CN104010657A (ru)
AR (6) AR088380A1 (ru)
AU (6) AU2012326080B2 (ru)
BR (6) BR112014009073A2 (ru)
CA (6) CA2851646A1 (ru)
CY (1) CY1121843T1 (ru)
DK (1) DK2768525T3 (ru)
EA (6) EA025663B1 (ru)
ES (1) ES2734070T3 (ru)
HK (6) HK1200722A1 (ru)
HR (1) HRP20191215T1 (ru)
HU (1) HUE045624T2 (ru)
IL (6) IL231825A0 (ru)
IN (3) IN2014CN02592A (ru)
LT (1) LT2768525T (ru)
MX (7) MX2014004732A (ru)
PL (1) PL2768525T3 (ru)
PT (1) PT2768525T (ru)
RS (1) RS59179B1 (ru)
SG (6) SG11201401576WA (ru)
SI (1) SI2768525T1 (ru)
TW (6) TWI619504B (ru)
WO (6) WO2013059406A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
JP6113176B2 (ja) * 2011-10-18 2017-04-12 コヒラス・バイオサイエンシズ・インコーポレイテッド キシリトールによって安定化されたエタネルセプト製剤
EA029193B1 (ru) * 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
IN2015KN00452A (ru) * 2012-09-11 2015-07-17 Coherus Biosciences Inc
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
KR20210041101A (ko) * 2013-10-24 2021-04-14 아스트라제네카 아베 안정한 수성 항체 제제
KR101712245B1 (ko) 2013-11-29 2017-03-06 아레스 트레이딩 에스.에이. TNFR 및 면역글로블린 Fc 영역을 포함하는 융합 단백질을 포함하는 액상 제제
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2021108427A1 (en) * 2019-11-26 2021-06-03 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
ES2833506T3 (es) 2014-12-22 2021-06-15 Ares Trading Sa Composición farmacéutica líquida
EP3236942A1 (en) * 2014-12-23 2017-11-01 Drug Discovery Laboratory AS Protein compositions and use thereof
RU2670166C1 (ru) * 2014-12-31 2018-10-18 ЭлДжи КЕМ, ЛТД. Способ получения слитого белка tnfr-fc с заданным содержанием примесей
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
JPWO2017179683A1 (ja) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
EP3528787A4 (en) * 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
CN111110842B (zh) * 2017-11-30 2020-12-11 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
CN111556744B (zh) * 2017-12-22 2023-12-29 韩商三星Bioepis 股份有限公司 包含vegf拮抗物的液体组合物
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
AU2022223669A1 (en) 2021-02-17 2023-08-03 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003522155A (ja) 2000-02-10 2003-07-22 ワイス 細胞損傷または細胞死を治療または阻害する方法
WO2002013860A1 (fr) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
CA2515539A1 (en) * 2003-02-28 2004-09-10 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
CN102020697B (zh) 2003-10-14 2014-10-29 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
DK1720972T3 (da) 2004-03-05 2014-04-14 Dsm Ip Assets Bv Fremgangsmåde til celledyrkning ved hjælp af fortløbende perfusion og vekslende tangentialt flow
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EA012801B1 (ru) * 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
US20100016677A1 (en) 2006-03-21 2010-01-21 Eugen Oetringer Devices for and Methods of Analyzing a Physiological Condition of a Physiological Subject Based on A Workload Related Property
CA2649538C (en) 2006-04-21 2014-06-03 Yatin Gokarn Buffering agents for biopharmaceutical formulations
AU2007321877B2 (en) * 2006-08-01 2011-11-03 Kineta Two, Llc Pharmaceutical manufacturing methods
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
LT2170390T (lt) * 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
CA2904458C (en) 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
SG187473A1 (en) * 2008-01-15 2013-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
MX2010009398A (es) 2008-02-29 2010-11-12 Biogen Idec Inc Proteinas de fusion de inmunoglobulinas purificadas y los metodos para su purificacion.
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP3431588A1 (en) 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US9428727B2 (en) 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
WO2011141926A2 (en) 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
JP6023715B2 (ja) 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
CA2833427C (en) * 2011-04-20 2019-09-24 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein tnfr:fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US20140142055A1 (en) 2011-06-29 2014-05-22 Insite Vision Corporation Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
KR102061355B1 (ko) 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
JP6280499B2 (ja) 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
JP6113176B2 (ja) * 2011-10-18 2017-04-12 コヒラス・バイオサイエンシズ・インコーポレイテッド キシリトールによって安定化されたエタネルセプト製剤
IN2015KN00452A (ru) 2012-09-11 2015-07-17 Coherus Biosciences Inc

Also Published As

Publication number Publication date
LT2768525T (lt) 2019-09-25
SI2768525T1 (sl) 2019-10-30
US10772963B2 (en) 2020-09-15
JP2014530864A (ja) 2014-11-20
AU2012326170B2 (en) 2016-12-22
WO2013059407A1 (en) 2013-04-25
EP2768535A1 (en) 2014-08-27
TW201325609A (zh) 2013-07-01
AU2012326168A1 (en) 2014-04-24
TW201325607A (zh) 2013-07-01
US9801942B2 (en) 2017-10-31
EA027325B1 (ru) 2017-07-31
US20190290768A1 (en) 2019-09-26
TW201325610A (zh) 2013-07-01
CA2851646A1 (en) 2013-04-25
US20190290765A1 (en) 2019-09-26
CN104010657A (zh) 2014-08-27
AU2012326084B2 (en) 2016-12-15
EA025267B1 (ru) 2016-12-30
JP6220788B2 (ja) 2017-10-25
KR20140091707A (ko) 2014-07-22
KR20200008021A (ko) 2020-01-22
BR112014009131A2 (pt) 2017-06-13
US20200405865A1 (en) 2020-12-31
EP2768533A1 (en) 2014-08-27
EA201490803A1 (ru) 2014-09-30
EP2768535A4 (en) 2015-03-11
US10980884B2 (en) 2021-04-20
AU2012326082B2 (en) 2016-12-15
JP2014530256A (ja) 2014-11-17
EA201490802A1 (ru) 2014-08-29
EP2768532A4 (en) 2015-03-11
AR088383A1 (es) 2014-05-28
US10987405B2 (en) 2021-04-27
AU2012326080B2 (en) 2017-02-16
IN2014CN02592A (ru) 2015-09-04
CN103998060A (zh) 2014-08-20
JP2014530862A (ja) 2014-11-20
MX2014004728A (es) 2015-05-15
MX367054B (es) 2019-08-02
US20130108632A1 (en) 2013-05-02
US20160317667A1 (en) 2016-11-03
EA026410B1 (ru) 2017-04-28
US20130108633A1 (en) 2013-05-02
EP2768854A4 (en) 2015-03-11
CN103998061A (zh) 2014-08-20
WO2013059408A1 (en) 2013-04-25
IL231829A0 (en) 2014-05-28
KR20140079491A (ko) 2014-06-26
US9770510B2 (en) 2017-09-26
HK1200722A1 (en) 2015-08-14
JP6104922B2 (ja) 2017-03-29
AU2012326171B2 (en) 2017-03-09
US9302002B2 (en) 2016-04-05
IL231825A0 (en) 2014-05-28
KR102068462B1 (ko) 2020-01-22
EP2768854A1 (en) 2014-08-27
AU2012326080A1 (en) 2014-04-24
CA2851642A1 (en) 2013-04-25
JP2014530255A (ja) 2014-11-17
EP2768531A4 (en) 2015-03-11
SG11201401567YA (en) 2014-07-30
CA2851639A1 (en) 2013-04-25
EA201490804A1 (ru) 2014-09-30
KR102163150B1 (ko) 2020-10-08
BR112014009146A8 (pt) 2017-06-20
CN104010658A (zh) 2014-08-27
US20130101640A1 (en) 2013-04-25
US20190314498A1 (en) 2019-10-17
HUE045624T2 (hu) 2020-01-28
EA201490817A1 (ru) 2014-09-30
MX2014004732A (es) 2015-05-15
JP6199298B2 (ja) 2017-09-20
MX2014004726A (es) 2015-05-15
JP6113176B2 (ja) 2017-04-12
SG11201401517VA (en) 2014-09-26
AU2012326082A1 (en) 2014-04-24
CN104011073A (zh) 2014-08-27
CA2851635A1 (en) 2013-04-25
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
AR088380A1 (es) 2014-05-28
US20180125982A1 (en) 2018-05-10
EP2768525A4 (en) 2015-07-15
US20190290766A1 (en) 2019-09-26
US20190298837A1 (en) 2019-10-03
BR112014009146A2 (pt) 2017-06-13
TW201325608A (zh) 2013-07-01
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
KR20140091705A (ko) 2014-07-22
IL231827A0 (en) 2014-05-28
US9943601B2 (en) 2018-04-17
CN103998060B (zh) 2016-12-21
WO2013059406A1 (en) 2013-04-25
CA2851651A1 (en) 2013-04-25
WO2013059412A1 (en) 2013-04-25
CN104011073B (zh) 2017-08-25
TWI619504B (zh) 2018-04-01
AU2012326084A1 (en) 2014-04-17
AR088460A1 (es) 2014-06-11
IL231826A0 (en) 2014-05-28
CY1121843T1 (el) 2020-07-31
EP2768531A1 (en) 2014-08-27
EP2768525B1 (en) 2019-06-19
EA201490801A1 (ru) 2014-09-30
IL231824A0 (en) 2014-05-28
PT2768525T (pt) 2019-07-17
EP2768533A4 (en) 2015-03-11
TW201325611A (zh) 2013-07-01
EA201490815A1 (ru) 2014-09-30
AR088379A1 (es) 2014-05-28
IN2014CN02527A (ru) 2015-06-26
DK2768525T3 (da) 2019-07-22
IL231828A0 (en) 2014-05-28
PL2768525T3 (pl) 2019-10-31
US10980885B2 (en) 2021-04-20
CA2851628A1 (en) 2013-04-25
US20190314500A1 (en) 2019-10-17
US20180193463A1 (en) 2018-07-12
BR112014009087A2 (pt) 2017-04-18
KR20140091706A (ko) 2014-07-22
BR112014009022A2 (pt) 2017-05-02
MX2014004734A (es) 2015-05-15
MX2014004725A (es) 2015-02-05
SG11201401562RA (en) 2014-09-26
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (ru) 2015-06-26
JP6110393B2 (ja) 2017-04-05
BR112014009031A2 (pt) 2017-05-09
JP6220789B2 (ja) 2017-10-25
US20190216930A1 (en) 2019-07-18
CN104010654A (zh) 2014-08-27
US11135267B2 (en) 2021-10-05
TW201325606A (zh) 2013-07-01
HK1200720A1 (en) 2015-08-14
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
HK1200721A1 (en) 2015-08-14
TWI644681B (zh) 2018-12-21
EP2768525A1 (en) 2014-08-27
JP2014530863A (ja) 2014-11-20
JP2014530254A (ja) 2014-11-17
EA025663B1 (ru) 2017-01-30
AU2012326170A1 (en) 2014-04-24
AU2012326171A1 (en) 2014-04-24
EP2768532A1 (en) 2014-08-27
AR088382A1 (es) 2014-05-28
US20130101584A1 (en) 2013-04-25
CN104010654B (zh) 2017-10-27
US10888619B2 (en) 2021-01-12
RS59179B1 (sr) 2019-10-31
US10213508B2 (en) 2019-02-26
SG11201401563SA (en) 2014-09-26
US20190314499A1 (en) 2019-10-17
MX2019009176A (es) 2019-10-07
AR088381A1 (es) 2014-05-28
TWI595883B (zh) 2017-08-21
HRP20191215T1 (hr) 2019-10-04
BR112014009131A8 (pt) 2017-06-20
US11129876B2 (en) 2021-09-28
ES2734070T3 (es) 2019-12-04
HK1200851A1 (en) 2015-08-14
BR112014009073A2 (pt) 2017-05-09
CA2851639C (en) 2020-12-29
US10376588B2 (en) 2019-08-13
US20190290767A1 (en) 2019-09-26
EA028520B1 (ru) 2017-11-30
KR20140097184A (ko) 2014-08-06
KR20140083037A (ko) 2014-07-03
US20160199489A1 (en) 2016-07-14
US20190184017A1 (en) 2019-06-20
SG11201401519RA (en) 2014-07-30
MX2014004733A (es) 2015-05-15
AU2012326168B2 (en) 2016-12-15
HK1200718A1 (en) 2015-08-14

Similar Documents

Publication Publication Date Title
HK1200851A1 (en) Etanercept formulations stabilized with amino acids
EP2771033A4 (en) PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
HK1210034A1 (en) Modified amino acids comprising an azido group
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
ZA201400692B (en) Stabilized subtilisin composition
PT2552242E (pt) Resumo
ZA201306118B (en) Lyophilized formulations
EP2709645A4 (en) ENHANCED PEPTIDE PHARMACEUTICAL AGENTS
ZA201309653B (en) Controlled release peptide formulations
GB201111183D0 (en) Peptide
SG10201606218WA (en) Purified Proteins
GB201208320D0 (en) Injector
EP2729164A4 (en) FORMULATIONS STABILIZING PROTEINS
HK1187628A1 (zh) 新型肽
HK1245089A1 (zh) 腸胃外注射用的穩定肽製劑
GB201303847D0 (en) Amino acid composition
GB201113089D0 (en) Protein hydrolysates
GB201116804D0 (en) Injector